Jiangsu Recbio Technology Co., Ltd. (2179.HK)
HKD 8.0
(2.56%)
HKD 8.0
(2.56%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -571.95 Million CNY | 20.47% |
| 2022 | -719.2 Million CNY | -2.35% |
| 2021 | -702.67 Million CNY | -232.81% |
| 2020 | -211.13 Million CNY | -3.6% |
| 2019 | -203.78 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -124.56 Million CNY | 0.0% |
| 2024 Q1 | -124.56 Million CNY | 16.79% |
| 2023 Q4 | -149.7 Million CNY | 0.0% |
| 2023 FY | -571.95 Million CNY | 20.47% |
| 2023 Q2 | -136.27 Million CNY | 0.0% |
| 2023 Q3 | -149.7 Million CNY | -9.85% |
| 2023 Q1 | -136.27 Million CNY | 26.93% |
| 2022 Q2 | -174.84 Million CNY | 0.0% |
| 2022 Q1 | -174.84 Million CNY | -28.53% |
| 2022 FY | -719.2 Million CNY | -2.35% |
| 2022 Q4 | -186.5 Million CNY | 0.0% |
| 2022 Q3 | -186.5 Million CNY | -6.67% |
| 2021 FY | -702.67 Million CNY | -232.81% |
| 2021 Q3 | -185.64 Million CNY | -12.41% |
| 2021 Q2 | -165.15 Million CNY | 0.0% |
| 2021 Q1 | -165.15 Million CNY | -29.96% |
| 2021 Q4 | -136.03 Million CNY | 26.72% |
| 2020 Q4 | -127.07 Million CNY | 0.0% |
| 2020 FY | -211.13 Million CNY | -3.6% |
| 2019 FY | -203.78 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 70.87 Million HKD | 906.983% |
| CK Life Sciences Int'l., (Holdings) Inc. | 17.25 Million HKD | 3415.693% |